# Systemic Immunity Triggered by Boron Neutron Capture Therapy via Manganese-Borate Complex

## TL;DR

A new boron neutron capture therapy activates systemic immunity and improves cancer treatment by combining targeted radiation with immune response.

## Contribution

A biomineralized albumin-based BNCT agent (Albumin@MnB) is introduced, which triggers systemic antitumor immunity and outperforms conventional agents.

## Key findings

- Albumin@MnB achieves potent tumor suppression at reduced boron doses.
- Albumin@MnB enhances intratumoral immune cell infiltration and suppresses distant tumor growth.
- The therapy synergizes with adoptive T cell immunotherapy and immune checkpoint inhibitors.

## Abstract

Conventional radiotherapy compromises antitumor immunity through collateral damage to immune cells. While boron neutron capture therapy (BNCT) enables tumor-selective 10B (n, α) 7Li reactions, clinical agents like boronophenylalanine (BPA) suffer from excessive dosing and exhibit immune-metabolic inertia. We report a biomineralized albumin-based BNCT agent (Albumin@MnB) synthesized from clinically accessible borax, manganese, and albumin, which unlocks neutron capture-triggered immunotherapeutic activation. Albumin@MnB achieves potent tumor suppression at reduced boron doses, demonstrating superior efficacy compared with BPA. Importantly, Albumin@MnB enhances intratumoral immune cell infiltration and suppresses distant tumor growth, synergizing with adoptive T cell immunotherapy and immune checkpoint inhibitors. By integrating tumor-specific radiolytic energy deposition with metabolic reprogramming and immune activation, this strategy establishes boron neutron capture immunotherapy (BNCI) as a multimodal therapeutic paradigm that bridges targeted radiolysis with systemic antitumor immunity.

Albumin@MnB induces potent localized cytotoxicity via neutron capture and triggers systemic anti-tumor immunity. This multimodal platform, bridging precision radiobiology with immunotherapy, demonstrates the feasibility of boron neutron capture immunotherapy (BNCI).Image 1